Is Rivaroxaban a Safe Choice for Apical Thrombus in Atrial Fibrillation Patients? A Case Report.

Autor: Aydin F; Eskisehir State Hospital Cardiology Department, Eskisehir, Turkey., Turgay Yildirim O; Eskisehir State Hospital Cardiology Department, Eskisehir, Turkey. Electronic address: ozgeturgay@gmail.com., Huseyinoglu Aydin A; Eskisehir State Hospital Cardiology Department, Eskisehir, Turkey., Dagtekin E; Eskisehir State Hospital Cardiology Department, Eskisehir, Turkey., Aksit E; Canakkale Onsekiz Mart University Cardiology Department, Canakkale, Turkey.
Jazyk: angličtina
Zdroj: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association [J Stroke Cerebrovasc Dis] 2018 Sep; Vol. 27 (9), pp. e203-e205. Date of Electronic Publication: 2018 May 04.
DOI: 10.1016/j.jstrokecerebrovasdis.2018.04.015
Abstrakt: Left ventricular thrombi are mostly seen in the akinetic segments of left ventricle and warfarin is the golden standard treatment. In our case, a 67-year-old male patient with ischemic dilated cardiomyopathy and atrial fibrillation was under warfarin treatment, but due to fluctuations in international normalized ratio, warfarin was discontinued and changed to rivaroxaban (20 mg once a day). He had a fixed thrombus measuring 1.80 × 1.12 cm 2 in the left ventricle under warfarin treatment before rivaroxaban use. After 6 months of rivaroxaban treatment, the thrombus regressed to 1.54 × 1.06 cm 2 without any embolic episode or bleeding. This case supports the finding that rivaroxaban can be a safe alternative to warfarin when warfarin cannot be used.
(Copyright © 2018 National Stroke Association. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: